Modification of the activity of mitochondrial monoamine oxidasesin vitro andin vivo
Histamine and Kinins
Received:
- 16 Downloads
Abstract
Treatment of bovine brain mitochondrial membranes with iproniazid (Ip) (1 mM, 15 min) inhibited monoamine oxidase (MAO) activity (substrates: 5-hydroxytryptamine, tyramine, dopamine) and significantly (about 7-fold) increased histamine daminating activity (HDA). A selective inhibitor of MAO-A clorgyline (contrary to deprenyl) prevented the increase in HDA. Ip (200 mg/kg; within 10–16 h after parenteral administration) markedly (about 6-fold) increased the level of the HDA) in brain mitochondria of mice and guinea pigs. At the same time, a decrease in content of histamine (Hi) and increase in content of 5-hydroxytryptamine was noted in the brains of mice. In anesthetized and non-anesthetized guinea pigs Ip decreased (or prevented) the bronchoconstriction and toxic effects caused by Hi. The antihistaminic effects of Ip are apparently due to its being able to induce reversible qualitative alteration (transformation) of the catalytic activity of the membranebround MAO of type A, which acquires as a result of this transformation potent HDA.
Keywords
Dopamine Histamine Mitochondrial Membrane Monoamine Catalytic Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- [1]V.Z. Gorkin,Monoamine oxidases: Versatility of catalytic properties and possible biological functions, Adv. Pharm.11, 1–50 (1973).Google Scholar
- [2]V.Z. Gorkin, Monoamine oxidase inhibitors and the transformation of monoamine oxidases. In (EdsG.E.W. Wolstenholm andJ. Knight)Monoamine Oxidase and its Inhibition, pp. 61–81 (Elsevier, Amsterdam, 1976.Google Scholar
- [3]J.P. Johnston,Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. Pharm.17, 1285–1297 (1968).CrossRefPubMedGoogle Scholar
- [4]J. Knoll, Monoamine oxidase inhibitors: Chemistry and pharmacology. InEnzyme Inhibitors as Drugs, pp. 151–171 (Ed.M. Sandler) Macmillan, London 1980.Google Scholar
- [5]E.A. Baumanis, L.E. Kalnina, T.A. Moskvitina andV.Z. Gorkin,Modification of brain mitochondrial monoamine oxidase activies by hydroxyethylhydrazide of cyanoacetic acid and some other monoamine oxidase inhibitors, Biochem. Pharm.26, 1059–1063 (1977).CrossRefPubMedGoogle Scholar
- [6]I.A. Goroshinskaya, Z.G. Bronovitskaya andV.Z. Gorkin,Effect of selective monoamine oxidase inhibitors on rat brain mitochondrial monoamine oxidase during hyperbaric oxygenation, Comm. Psychopharm.1, 39–47 (1977).Google Scholar
- [7]K.K. Shatemirova, I.V. Veryovkina andV.Z. Gorkin,On the transformation of mitochondrial monoamine oxidases of the types A and B. Bull. Exp. Biol. Med. (Moscow)6, 669–670 (1977).Google Scholar
- [8]R.S. Krivchenkova, Estimation of succinate dehydrogenase and cytochrome oxidase activities in mitochondrial suspensions. InModern Methods in Biochemistry, pp. 44–49 (Ed.V.N. Orekhovich) Meditzina, Moscow 1977.Google Scholar
- [9]V.K. Gorodetzky andI.L. Selivanov,Use of phenolphthaline for estimation of glucose by an enzymatic (glucose oxidase) method. Appl. Biochem. Microbiol. (Moscow)5, 353–359 (1969).Google Scholar
- [10]S.A. Mescheryakova andTs.A. Gerasimova The fluorimetric method of histamine and serotonin determination in the in the same sample, Lab. Practice (Moscow)N11, 670–672 (1974).Google Scholar
- [11]M.E. Kaminka,Procedures used in recording the bronchial muscles tone in guinea pigs. Pharmac. Toxicol. (Moscow)38, 229–231 (1975).Google Scholar
- [12]Z.I. Akopyan, L.N. Stesina andV.Z. Gorkin,New properties of highly purified bovine liver mitochondrial monoamine oxidase. Reversible oxidation of sulfhydral groups and reversible qualitative alteration (transformation) of the substrate and inhibitor specificity, J. Biol. Chem.246, 4610–4618 (1971).Google Scholar
- [13]N.G. Watson,Studies on mammalian histidine decarboxylase, Br. J. Pharmac.11, 119–127 (1956).Google Scholar
- [14]M. Strolin Benedetti, J.F. Ancher andN. Sontag,Monoamine oxidase inhibitors and histamine metabolism, Experientia36, 818–820 (1980).CrossRefPubMedGoogle Scholar
- [15]M.D. Mashkovsky,Biochemical pharmacology of hydrazine derivatives and their role in treatment of mental diseases,J. All-Union D.I. Mendeleev's Chem. Soc. [Moscow] 9, 433–437 (1964).Google Scholar
- [16]Ch.B. Kairane, E.A. Baumanis, E.B. Burlakova, V.Z. Gorkin, I.E. Kalnina andE.M. Molochkina,Alterations in the anti-oxidative activity of lipids of mice organs and of the monoamine oxidase activity under the effect of dibenzylhydrazide of d,l.-malic acid, Vop. med. Khim. (Problems of Med. Chem., Moscow)25, 776–781 (1979).Google Scholar
- [17]S.M. Russell, J. Davey andR.J. Mayer, The topography and turnover of mitochondrial monoamine oxidase. InMonoamine Oxidase: Structure, Function, and Altered Functions, pp. 265–272 (EdsT.P. Singer, R.W. von Korff andD.L. Murphy) Academic Press, New York 1979.Google Scholar
- [18]T.P. Singer, Active site-directed irreversible inhibitors of monoamine oxidase. InMonoamine Oxidase: Structure, Function, and Altered Functions, pp. 7–24 (EdsT.P. Singer, R.W. von Korff andD.L. Murphy) Academic Press, New York 1979.Google Scholar
- [19]I. Rubana, G. Klimova andE. Baumanis,The effect of monoamine oxidase inhibitors of hydrazine series on oxidative deamination of putrescine by diamine oxidase, Proc. Latvian Acad. Sci. RigaN3, 98–105 (1975).Google Scholar
Copyright information
© Birkhäuser Verlag 1981